{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Trametinib&page=3", "query": { "intervention": "Trametinib", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 180, "total_pages": 18, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Trametinib&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Trametinib&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T23:23:08.029Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01619774", "title": "An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "GSK2118436", "type": "DRUG" }, { "name": "GSK1120212", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 28, "start_date": "2012-09", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2016-12-12", "last_synced_at": "2026-10-21T23:23:08.029Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01619774" }, { "nct_id": "NCT04439318", "title": "Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Lymphoma", "Advanced Malignant Solid Neoplasm", "Hematopoietic and Lymphoid Cell Neoplasm", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Trametinib Dimethyl Sulfoxide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2016-02-25", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-10-21T23:23:08.029Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04439318" }, { "nct_id": "NCT01467310", "title": "Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "GSK1120212", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 15, "start_date": "2012-01", "completion_date": "2016-03-21", "has_results": false, "last_update_posted_date": "2020-09-02", "last_synced_at": "2026-10-21T23:23:08.029Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01467310" }, { "nct_id": "NCT03919071", "title": "Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anaplastic Astrocytoma", "Anaplastic Astrocytoma, Not Otherwise Specified", "Anaplastic Ganglioglioma", "Anaplastic Pleomorphic Xanthoastrocytoma", "Glioblastoma", "Malignant Glioma", "WHO Grade 3 Glioma", "WHO Grade 4 Glioma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Dabrafenib Mesylate", "type": "DRUG" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Trametinib Dimethyl Sulfoxide", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "3 Years to 25 Years" }, "enrollment_count": 58, "start_date": "2020-02-20", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-10-21T23:23:08.029Z", "location_count": 130, "location_summary": "Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 106 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03919071" }, { "nct_id": "NCT02110355", "title": "A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignancy", "Advanced Solid Tumors", "Cancer", "Oncology", "Oncology Patients", "Tumors", "Melanoma" ], "interventions": [ { "name": "AMG 232", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "Dabrafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kartos Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2014-12-19", "completion_date": "2018-12-27", "has_results": false, "last_update_posted_date": "2021-03-26", "last_synced_at": "2026-10-21T23:23:08.029Z", "location_count": 5, "location_summary": "Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02110355" }, { "nct_id": "NCT05358249", "title": "Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "KRAS G12C Mutant Solid Tumors", "Carcinoma, Non-Small Cell Lung", "Carcinoma, Non-Small-Cell Lung", "Non-Small Cell Lung Cancer", "Non-Small Cell Lung Carcinoma", "Nonsmall Cell Lung Cancer", "Colorectal Cancer", "Colorectal Carcinoma", "Colorectal Neoplasms", "Colorectal Tumors", "Neoplasms, Colorectal" ], "interventions": [ { "name": "JDQ443", "type": "DRUG" }, { "name": "trametinib", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "cetuximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 74, "start_date": "2022-10-24", "completion_date": "2026-09-28", "has_results": false, "last_update_posted_date": "2026-10-21", "last_synced_at": "2026-10-21T23:23:08.029Z", "location_count": 3, "location_summary": "Boston, Massachusetts • New York, New York", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05358249" }, { "nct_id": "NCT03975829", "title": "Pediatric Long-Term Follow-up and Rollover Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diffuse Astrocytoma", "Anaplastic Astrocytoma", "Astrocytoma", "Oligodendroglioma, Childhood", "Anaplastic Oligodendroglioma", "Glioblastoma", "Pilocytic Astrocytoma", "Giant Cell Astrocytoma", "Pleomorphic Xanthoastrocytoma", "Anaplastic Pleomorphic Xanthoastrocytoma", "Angiocentric Glioma", "Chordoid Glioma of Third Ventricle", "Gangliocytoma", "Ganglioglioma", "Anaplastic Ganglioglioma", "Dysplastic Gangliocytoma of Cerebrellum", "Desmoplastic Infantile Astrocytoma and Ganglioglioma", "Papillary Glioneuronal Tumor", "Rosette-forming Glioneuronal Tumor", "Central Neurocytoma", "Extraventricular Neurocytoma", "Cerebellar Liponeurocytoma", "Neurofibromatosis Type 1" ], "interventions": [ { "name": "dabrafenib", "type": "DRUG" }, { "name": "trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "99 Years", "sex": "ALL", "summary": "1 Year to 99 Years" }, "enrollment_count": 163, "start_date": "2019-11-04", "completion_date": "2026-11-05", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-10-21T23:23:08.029Z", "location_count": 11, "location_summary": "Phoenix, Arizona • Washington D.C., District of Columbia • Miami, Florida + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03975829" }, { "nct_id": "NCT05611229", "title": "Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Dabrafenib+Trametinib", "type": "COMBINATION_PRODUCT" }, { "name": "Ipilimumab+Nivolumab", "type": "COMBINATION_PRODUCT" }, { "name": "Vemurafenib+Cobimetinib", "type": "COMBINATION_PRODUCT" }, { "name": "Encorafenib+Binimetinib", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1975, "start_date": "2020-06-16", "completion_date": "2021-12-03", "has_results": false, "last_update_posted_date": "2023-04-06", "last_synced_at": "2026-10-21T23:23:08.029Z", "location_count": 1, "location_summary": "East Hanover, New Jersey", "locations": [ { "city": "East Hanover", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05611229" }, { "nct_id": "NCT07543822", "title": "24VA022; VATCH Alpelisib for TIE2/PIK3CA Pathway VAs", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Vascular Anomalies", "Vascular Anomaly", "TIE2/PIK3CA Pathway Driven Vascular Anomalies" ], "interventions": [ { "name": "alpelisib (BYL719)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Hospital of Philadelphia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "2 Years to 30 Years" }, "enrollment_count": 61, "start_date": "2025-08-27", "completion_date": "2030-10-27", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-10-21T23:23:08.029Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07543822" }, { "nct_id": "NCT03340506", "title": "Dabrafenib and/or Trametinib Rollover Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Melanoma", "Non Small Cell Lung Cancer", "Solid Tumor", "Rare Cancers", "High Grade Glioma" ], "interventions": [ { "name": "dabrafenib", "type": "DRUG" }, { "name": "trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 100, "start_date": "2018-01-26", "completion_date": "2032-12-28", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-10-21T23:23:08.029Z", "location_count": 4, "location_summary": "Scottsdale, Arizona • Bethesda, Maryland • Columbus, Ohio + 1 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03340506" } ] }